How to use the speech recognition tool?
A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).
Status of the trial: Active, Not recruiting
Orphan Drug Recognition: No
- Opening Date: 2019-04-04
- Closing Date: 2021-12-04
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
- Retinal Rare Eye Diseases (WG1)
This ERN is supported by: